PILA PHARMA AB (PILA) AI Stock Analysis

• Market Cap: kr76.85M
• Dividend Yield: N/A
• Average Volume (3M): 235.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SE
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 42,084,415
• 10 Day Avg. Volume: 194,482
• 30 Day Avg. Volume: 235,519
• PEG Ratio: 1.33
• Price to Book (P/B): 18.15
• Price to Sales (P/S): 123.19
• P/FCF Ratio: -12.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: kr2.00 ▼(-9.09% Downside)

The score is driven primarily by weak financial performance (declining revenue, persistent losses, and worsening negative free cash flow), partially offset by low leverage (no debt). Technicals are neutral-to-weak (below key moving averages with negative MACD), and valuation offers limited support due to negative earnings and no dividend data.

Positive Factors

Large addressable market focus (diabetes, obesity)

Targeting type 2 diabetes and obesity aligns the company with structurally growing, chronic-therapy markets. A successful therapeutic from its TRPV1 antagonist program (XEN-D0501) would meet persistent demand, supporting sustained commercial potential and long-term revenue opportunities.

Low leverage with no recorded debt

Zero total debt reduces fixed financial obligations and interest exposure, preserving operational flexibility during lengthy clinical development. This balance-sheet conservatism lowers immediate default risk and gives management optionality to time external funding from a stronger negotiating position.

Extremely lean organizational footprint

A single-employee headcount implies a highly outsourced, low fixed-cost model, which can extend cash runway and focus scarce capital on R&D. Over the medium term this capital efficiency supports survival through trial phases, though it requires disciplined external partnerships for scale.

Negative Factors

Persistent negative cash flow and accelerating burn

Consistent negative operating and free cash flow indicate the company cannot self-fund development. Accelerating cash burn narrows runway, raises near-term financing needs, and increases the probability of dilution or disruptive financing solutions, a material structural weakness for a clinical-stage biotech.

Eroding equity cushion and weakened balance sheet

Sharp depletion of equity reduces the company’s financial buffer to absorb ongoing R&D losses and adverse trial outcomes. A thinner equity base restricts strategic flexibility and elevates the likelihood and potential severity of dilutive financings over the next several quarters.

Small, declining revenue and persistent operating losses

Declining revenue and repeated operating losses demonstrate limited current commercial traction and weak unit economics. Negative gross profit in the latest year signals structural cost-revenue mismatches, making long-term viability contingent on successful clinical progress rather than existing business operations.

PILA PHARMA AB Business Overview & Revenue Model

Company Description

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.

How the Company Makes Money

PILA PHARMA AB generates revenue primarily through the development and commercialization of its pharmaceutical products targeting metabolic disorders. The company's revenue model includes out-licensing its drug candidates to larger pharmaceutical companies, which involves upfront payments, milestone payments, and royalties on future sales. Additionally, PILA may engage in collaborative research agreements and partnerships to fund its R&D activities, where partners contribute resources and funding in exchange for certain rights to the developed products. The success of PILA's revenue streams is heavily dependent on the successful progression of its drug candidates through clinical trials and regulatory approval processes.

PILA PHARMA AB Financial Statement Overview

Summary

PILA PHARMA AB faces financial headwinds with declining revenue, persistent losses, and negative cash flows. Despite a strong equity base and no debt, the company's financial performance reflects operational and market challenges typical in the biotechnology industry. Future sustainability will depend on improving revenue streams and managing cash outflows efficiently.

Income Statement

The company shows a declining revenue trend, with total revenue decreasing from 1,463,020 in 2023 to 775,000 in 2024. Gross profit margins have been consistently low, reflecting operational challenges. The net profit margin remains negative due to continued losses. EBIT and EBITDA margins are also deeply negative, indicating significant operational inefficiencies.

Balance Sheet

PILA PHARMA AB maintains a strong equity position with a debt-to-equity ratio of zero, reflecting no reliance on debt financing. However, the company's equity ratio has declined over the years, and total assets have decreased as well. While the cash position appears healthy, diminishing stockholders' equity and assets pose potential risks.

Cash Flow

The company struggles with negative free cash flow, which increased from -4,854,000 in 2023 to -7,823,000 in 2024. Operating cash flow remains negative, though financing activities have provided some cash inflow. The free cash flow to net income ratio indicates that operational cash generation is not covering losses, challenging future liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	957.89K	775.00K	1.46M	1.88M	719.23K	0.00
Gross Profit	179.89K	-8.12M	1.46M	1.88M	680.94K	-492.39K
EBITDA	-7.04M	-10.11M	-8.81M	-26.76M	-17.16M	-3.36M
Net Income	-11.26M	-11.24M	-9.93M	-26.78M	-17.21M	-10.58M
Balance Sheet
Total Assets	3.48M	6.22M	8.46M	10.89M	31.81M	5.37M
Cash, Cash Equivalents and Short-Term Investments	1.08M	4.89M	5.95M	7.24M	28.21M	1.91M
Total Debt	0.00	0.00	773.08K	0.00	0.00	500.00K
Total Liabilities	2.32M	963.00K	1.79M	1.36M	1.51M	1.95M
Stockholders Equity	1.16M	5.26M	6.66M	9.53M	30.30M	3.42M
Cash Flow
Free Cash Flow	-8.22M	-7.82M	-4.85M	-9.09M	-9.36M	-2.00M
Operating Cash Flow	-8.22M	-7.82M	-4.85M	-9.09M	-9.36M	-2.00M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	6.76M	6.76M	3.56M	-11.88M	35.67M	-158.07K

PILA PHARMA AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PILA, the sentiment is Neutral. The current price of 2.2 is above the 20-day moving average (MA) of 2.09, below the 50-day MA of 2.21, and below the 200-day MA of 2.54, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 50.75 is Neutral, neither overbought nor oversold. The STOCH value of 41.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:PILA.

PILA PHARMA AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NXTCL	52 Neutral	kr82.65M	-2.01	-52.45%	―	2.56%	52.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EXPRS2	46 Neutral	kr55.99M	-0.86	-88.65%	―	8.46%	11.73%
PILA	44 Neutral	kr76.85M	-5.45	-601.02%	―	―	―
BIOSGN	42 Neutral	kr93.93M	-2.90	-201.21%	―	―	49.09%
LPGO	41 Neutral	kr8.73M	-0.11	-213.85%	―	―	―
SPAGO	40 Underperform	kr76.74M	-2.03	-106.95%	―	-48.15%	51.95%